- Home
- HOLO vs IMMX Comparison
HOLO vs IMMX Comparison
Compare HOLO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- IMMX
- Stock Information
- Founded
- HOLO 2018
- IMMX 2014
- Country
- HOLO China
- IMMX United States
- Employees
- HOLO N/A
- IMMX N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- HOLO Technology
- IMMX Health Care
- Exchange
- HOLO Nasdaq
- IMMX Nasdaq
- Market Cap
- HOLO 50.1M
- IMMX 44.8M
- IPO Year
- HOLO N/A
- IMMX 2021
- Fundamental
- Price
- HOLO $0.94
- IMMX $1.59
- Analyst Decision
- HOLO
- IMMX Strong Buy
- Analyst Count
- HOLO 0
- IMMX 1
- Target Price
- HOLO N/A
- IMMX $7.00
- AVG Volume (30 Days)
- HOLO 32.8M
- IMMX 57.1K
- Earning Date
- HOLO 01-01-0001
- IMMX 03-28-2025
- Dividend Yield
- HOLO N/A
- IMMX N/A
- EPS Growth
- HOLO N/A
- IMMX N/A
- EPS
- HOLO N/A
- IMMX N/A
- Revenue
- HOLO $32,242,196.00
- IMMX N/A
- Revenue This Year
- HOLO N/A
- IMMX N/A
- Revenue Next Year
- HOLO N/A
- IMMX $600.00
- P/E Ratio
- HOLO N/A
- IMMX N/A
- Revenue Growth
- HOLO 326.95
- IMMX N/A
- 52 Week Low
- HOLO $0.92
- IMMX $1.26
- 52 Week High
- HOLO $171.60
- IMMX $3.35
- Technical
- Relative Strength Index (RSI)
- HOLO 40.80
- IMMX 41.29
- Support Level
- HOLO $0.92
- IMMX $1.51
- Resistance Level
- HOLO $1.15
- IMMX $1.68
- Average True Range (ATR)
- HOLO 0.17
- IMMX 0.13
- MACD
- HOLO 0.02
- IMMX 0.00
- Stochastic Oscillator
- HOLO 9.18
- IMMX 37.13
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.